Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome

Southern Medical Journal

Volumn 100, Issue 1, 2007, Pages 27-32

  Sezgin, Canfeza ^a   Kurt, Ender ^b   Evrensel, Turkan ^b   Ozdemir, Necmettin ^b   Manavoglu, Osman ^b   Goker, Erdem ^b  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NONE

Author keywords

Capecitabine; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONJUNCTIVITIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; FATIGUE; HAND FOOT SYNDROME; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NAUSEA; SIDE EFFECT; TOXIC HEPATITIS; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PRODRUGS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33846247078     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000252968.87824.19     Document Type: Article

References (21)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
2. Harris J, Morrow M, Norton L. Malign tumors of the breast. In: DeVita Jr, VT Hellman Rosenberg SA, eds. Cancer: Principles and Practices of Oncology. 5th edition. Philadelphia, PA, Lippincott-Raven, 1997, pp 1557-1606.
3. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
4. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291-297.
5. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
6. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001;92:1759-1768.
7. Reichardt P, von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-1233.
8. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004;40:536-542.
9. Hennessy BT, Gauthier AM, Michaud LB, et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005;16:1289-1296.
10. O'Shaughnessy J, Blum J. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine). Proc Am Soc Clin Oncol 2000;19:400.
11. Bajetta E, Procopio G, Celio G, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155-2161.
12. Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-1266.
13. Berns EM, Foekens JA, van Staveren IL, et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995;159:11-18.
14. Benz C, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with Her2/neu. Breast Cancer Res Treat 1992;24:85-95.
15. Sunderland MC, McGuire WL. Oncogenes as clinical prognostic indicators. Cancer Treat Res 1991;53:3-22.
16. Borg A, Baldetorp B, Ferno M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994;81:137-144.
17. Sjöström J, Blomqvist C, Heikkila P, et al. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 2000;6:3103-3110.
18. Middleton LP, Palacios DM, Bryant BR, et al. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol 2000;24:1650-1656.
19. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 2000;13:866-873.
20. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med 2001;344:783-792.
21. Pierga JY, Fumoleau P, Brewer Y, et al. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French Compassionate Use Program. Breast Cancer Res Treat 2004;88:117-129.